DV
Dividend Vision

DBVT — DBV Technologies

DBV Technologies (DBVT)

Total return is -69.4% over the past 11.8 years, 459.9 points behind SPY at 390.5%. Its deepest 1-year drawdown was 45.1%.

DBV Technologies is a clinical-stage biopharmaceutical company developing epicutaneous immunotherapy products for food allergies and related conditions, with its lead candidate Viaskin Peanut having completed Phase 3 trials and earlier-stage programs addressing milk allergy, celiac disease, and diagnostic tools. The company does not currently distribute dividends. This security appeals to investors seeking exposure to biotech development risk rather than income generation.

DBVT key facts

Asset type
Stock
Asset class
Equity
Inception date
10/22/2014
Last close
$14.02
Market cap
$869,990,592
Average volume
128500.0
Beta
-0.212
Payout ratio
0.0
Forward P/E
0.0
EPS
$-3.50